Evaluation of the Effectiveness of Eradication Therapy Based on Potassium-Competitive Acid Blockers in Patients with Helicobakter Pylori Associated Chronic Gastritis
Main Article Content
Abstract
Article Details
References
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. //Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. /Gut. 2007; 56:772-781. doi:10.1136/gut.2006.101634.
Malfertheiner P, Megraud F , O'Morain CA, et al .//Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report/ Gut 2017;66:6–30.doi:10.1136/gutjnl-2016-312288.
Sugano K, Tack J, Kuipers EJ, et al Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64:135367.
Каримов М.М., Собирова Г.Н., Саатов З.З., Исламова Ш.З., Рустамова С.Т. /Распространенность и молекулярно-генетические характеристики H. Pylori в Узбекистане//Эффективная фармакотерапия, 28(15) 2019. Москва. С.48-51.
Graham DY, Dore MP. //Helicobacter pylori therapy: a paradigm shift/Expert Rev Anti Infect Ther. 2016;14(6):577-585.
Sobirova G.N., Karimov M.M., Abdullaeva U.K., Aslonova I.J., Tulyzganova F.M. //Serological Diagnostics of atrophy of the gastric mucosa / American Journal of Medical Science and Pharmaceutical Research 2020, 02 (12): 118-124.
Malfertheiner P., Megraud F., Rokkas //Th. et all. 4 Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report/Gut. 2022 Aug 8; gutjnl-2022-327745.
Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Ashida K. //A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis/ Therap Adv Gastroenterol. 2017 Jun;10(6):439-451.
Mori H, Suzuki H. //Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker/ J Neurogastroenterol Motil. 2019 Jan 31;25(1):6-14. doi: 10.5056/jnm18139.
Akazawa Y, Fukuda D, Fukuda Y.//Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence/Therap Adv Gastroenterol. 2016;9(6):845-852. doi:10.1177/1756283X16668093.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. //Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study/ Gut. 2016;65(9):1439-1446. doi:10.1136/gutjnl-2015-311304.
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. //The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPIBased Low-Dose Clarithromycin Triple Therapy/ Am J Gastroenterol. 2016;111(7):949-956. doi:10.1038/ajg.2016.182.